Experienced in Tardive Dyskinesia

Dr. Anne M. Connolly

Pediatric Neurology | Neurology
5675 Venture Dr, 
Dublin, OH 
Accepting New Patients
Experienced in Tardive Dyskinesia
5675 Venture Dr, 
Dublin, OH 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Anne Connolly is a Pediatric Neurologist and a Neurologist in Dublin, Ohio. Dr. Connolly is rated as an Experienced provider by MediFind in the treatment of Tardive Dyskinesia. Her top areas of expertise are Becker Muscular Dystrophy, Duchenne Muscular Dystrophy, Spinal Muscular Atrophy (SMA), and Primary Lateral Sclerosis. Dr. Connolly is currently accepting new patients.

Her clinical research consists of co-authoring 123 peer reviewed articles and participating in 11 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Tardive Dyskinesia.

Specialties
Pediatric Neurology
Neurology
Licenses
Neurology with Special Qualifications in Neurology in OH
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
CareSource
  • HMO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
UPMC
  • EPO
  • PPO
View 5 Less Insurance Carriers -

Locations

5675 Venture Dr, Dublin, OH 43017
Other Locations
433 N Cleveland Ave, Westerville, OH 43082
3949 N Main St, Findlay, OH 45840
455 Executive Campus Dr, Westerville, OH 43082
555 S 18th St, Columbus, OH 43205
536 S Trimble Rd, Mansfield, OH 44906
6435 E Broad St, Columbus, OH 43213

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

11 Clinical Trials

A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Trial Evaluating the Safety and Efficacy of Intravenous Delivery of Allogeneic Cardiosphere-Derived Cells in Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: May 28, 2025
Intervention Type: Drug, Biological
Study Phase: Phase 2
Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)
Systemic Gene Delivery Phase I/IIa Clinical Trial for Duchenne Muscular Dystrophy Using rAAVrh74.MHCK7.Micro-dystrophin (microDys-IV-001)
Enrollment Status: Completed
Publish Date: November 14, 2024
Intervention Type: Genetic
Study Drug: SRP-9001
Study Phase: Phase 1/Phase 2
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Trial of Pamrevlumab (FG-3019), a Monoclonal Antibody to Connective Tissue Growth Factor, in Non-Ambulatory Subjects With Duchenne Muscular Dystrophy
Enrollment Status: Terminated
Publish Date: August 27, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 2
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
A Phase 3, Randomized, Double-Blind Trial of Pamrevlumab (FG-3019) or Placebo in Combination With Systemic Corticosteroids in Subjects With Non-ambulatory Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Terminated
Publish Date: March 12, 2024
Intervention Type: Drug
Study Drug: Pamrevlumab
Study Phase: Phase 3
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Phase I, Open-Label, Dose Comparison Study of AVXS-101 for Sitting But Non-ambulatory Patients With Spinal Muscular Atrophy
Enrollment Status: Terminated
Publish Date: April 24, 2023
Intervention Type: Biological
Study Phase: Phase 1
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Randomised, Double Blind, Placebo Controlled, Multicentre Study to Evaluate the Efficacy and Safety of Givinostat in Ambulant Patients With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: February 02, 2023
Intervention Type: Drug
Study Drug: Givinostat
Study Phase: Phase 3
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
A Phase 1 Trial to Evaluate the Safety, Tolerability, and Pharmacokinetics of a Single Dose of SRP-5051 in Patients With Duchenne Muscular Dystrophy Amenable to Exon 51 Skipping Treatment
Enrollment Status: Completed
Publish Date: July 06, 2022
Intervention Type: Drug
Study Phase: Phase 1
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
A Phase II, Dose Finding Study to Assess the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NS-065/NCNP-01 in Boys With Duchenne Muscular Dystrophy (DMD)
Enrollment Status: Completed
Publish Date: December 07, 2021
Intervention Type: Drug
Study Phase: Phase 2
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
An Open-Label, Multi-Center, Study With a Concurrent Untreated Control Arm to Evaluate the Efficacy and Safety of Eteplirsen in Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 3
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
An Open-Label, Multi-Center Study to Evaluate the Safety, Efficacy and Tolerability of Eteplirsen in Early Stage Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: January 25, 2021
Intervention Type: Drug
Study Phase: Phase 2
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Phase 2 Historically Controlled Trial of Corticosteroids in Young Boys With Duchenne Muscular Dystrophy
Enrollment Status: Completed
Publish Date: December 21, 2018
Intervention Type: Drug
Study Phase: Phase 2
View 10 Less Clinical Trials

123 Total Publications

In memoriam: Dr. Julaine Marie Florence (1953-2025).
In memoriam: Dr. Julaine Marie Florence (1953-2025).
Journal: Neuromuscular disorders : NMD
Published: July 30, 2025
Similar Doctors
Advanced in Tardive Dyskinesia
Dr. Angela M. Hardwick
Neurology
Advanced in Tardive Dyskinesia
Dr. Angela M. Hardwick
Neurology

Ohiohealth Corporation

3535 Olentangy River Rd, S1501, 
Columbus, OH 
 (7.5 miles away)
614-533-5500
Languages Spoken:
English
See accepted insurances
Accepting New Patients

Angela Hardwick is a Neurologist in Columbus, Ohio. Dr. Hardwick is rated as a Distinguished provider by MediFind in the treatment of Tardive Dyskinesia. Her top areas of expertise are Movement Disorders, Parkinson's Disease, Essential Tremor, and Tardive Dyskinesia. Dr. Hardwick is currently accepting new patients.

Advanced in Tardive Dyskinesia
Dr. Shnehal C. Patel
Neurology
Advanced in Tardive Dyskinesia
Dr. Shnehal C. Patel
Neurology

Ohiohealth Corporation

4191 Kelnor Dr, Suite 200, 
Grove City, OH 
 (15.9 miles away)
614-544-1891
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

Shnehal Patel is a Neurologist in Grove City, Ohio. Dr. Patel is rated as an Advanced provider by MediFind in the treatment of Tardive Dyskinesia. His top areas of expertise are Essential Tremor, Parkinson's Disease, Movement Disorders, and Secondary Parkinsonism. Dr. Patel is currently accepting new patients.

Advanced in Tardive Dyskinesia
Dr. Siyun Li
Neurology
Advanced in Tardive Dyskinesia
Dr. Siyun Li
Neurology

Adena Medical Group LLC

4437 State Route 159 125, 
Chillicothe, OH 
 (49.4 miles away)
740-779-4570
Languages Spoken:
English, Mandarin
See accepted insurances
Accepting New Patients

Siyun Li is a Neurologist in Chillicothe, Ohio. Dr. Li is rated as a Distinguished provider by MediFind in the treatment of Tardive Dyskinesia. His top areas of expertise are Obstructive Sleep Apnea, Epilepsy, Essential Tremor, and Memory Loss. Dr. Li is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Connolly's expertise for a condition
ConditionClose
View All 39 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile